Everything to know about cystic fibrosis and what causes it
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
Charleston Moms charity event supports finding a cure for cystic fibrosis
Hundreds of Lowcountry moms danced the night away all in support of research to support a treatment for a genetic disorder.
The Macomb Daily9h
For caregivers, a friend who ‘gets it’ can be a lifeline
I seesawed between steely independence and a longing to lean on others — to stop pretending I was coping when I was ready to ...
The Lancet10d
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta
The effect of cystic fibrosis on many organs and the frequent lung infections means that it is mostly diagnosed in childhood.
IFLScience on MSN1d
Inhalable Cystic Fibrosis Gene Therapy 24 Years In The Making Enters Clinical Trials
A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...
Medscape4d
Novel Triple Combination Therapy May Transform Cystic Fibrosis Care in Children
Once-daily vanzacaftor-tezacaftor-deutivacaftor was safe and well-tolerated in children with cystic fibrosis, while ...
pharmaphorum1d
Trial of Boehringer's cystic fibrosis gene therapy imminent
An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.
pulmonologyadvisor9d
Cystic Fibrosis: GI Symptom Relief From ETI Wanes Over Long Term
In adults with cystic fibrosis, gastrointestinal symptoms initially improve with ETI but most do not consistently improve with longer-term use.
PharmiWeb2d
Cystic Fibrosis Market: Trends, Insights, and Growth Projections 2025-2035
The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, ...
Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
2minutemedicine.com1d
Characterization of meconium-related obstruction and outcomes in term and preterm infants
Meconium-Related Obstruction and Clinical Outcomes in Term and Preterm Infants 1. Nearly 95% of cases of meconium-related obstruction (MRO) occur in the absence of cystic fibrosis or Hirschsprung ...